Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07186621 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
Trial Details
NCT Number NCT07186621
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Peking University People's Hospital, Nanfang Hospital, Southern Medical University, Beijing 302 Hospital, Beijing Ditan Hospital, Eastern Hepatobiliary Surgery Hospital
Conditions Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE, Narrow Margin
Enrollment 286 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov